Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer.

BACKGROUND No standard chemotherapy is available for anaplastic thyroid cancer (ATC). Drug-loaded nanobubbles (NBs) are a promising innovative anticancer drug formulation, and combining them with an externally applied trigger may further control drug release at the target region. Extracorporeal shock waves (ESWs) are acoustic waves widely used in urology and orthopedics, with no side effects. The aim of the present work was to combine ESWs and new doxorubicin-loaded glycol chitosan NBs in order to target doxorubicin and enhance its antitumor effect in ATC cell lines. METHODS CAL-62 and 8305C cells were treated with empty NBs, fluorescent NBs, free doxorubicin, and doxorubicin-loaded NBs in the presence or in the absence of ESWs. NB entrance was evaluated by fluorescence microscopy and flow cytofluorimetry. Cell viability was assessed by Trypan Blue exclusion and WST-1 proliferation assays. Doxorubicin intracellular content was measured by high-performance liquid chromatography. RESULTS Treatment with empty NBs and ESWs, even in combination, was safe, as cell viability and growth were not affected. Loading NBs with doxorubicin and combining them with ESWs generated the highest cytotoxic effect, resulting in drug GI50 reduction of about 40%. Mechanistically, ESWs triggered intracellular drug release from NBs, resulting in the highest nuclear drug content. CONCLUSIONS Combined treatment with doxorubicin-loaded NBs and ESWs is a promising drug delivery tool for ATC treatment with the possibility of using lower doxorubicin doses and thus limiting its systemic side effects.

[1]  M. Shah,et al.  Anaplastic thyroid cancer , 2015, Current opinion in endocrinology, diabetes, and obesity.

[2]  Xiaojuan Pang,et al.  A dual pH/thermal responsive nanocarrier for combined chemo-thermotherapy based on a copper-doxorubicin complex and gold nanorods. , 2015, Nanoscale.

[3]  Chen Jiang,et al.  Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. , 2015, ACS applied materials & interfaces.

[4]  J. Shah,et al.  Anaplastic Thyroid Carcinoma, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  M. Ramezani,et al.  The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  P. Giustetto,et al.  Preparation and in vitro characterization of chitosan nanobubbles as theranostic agents. , 2015, Colloids and surfaces. B, Biointerfaces.

[7]  F. Atyabi,et al.  Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[8]  S. Mane,et al.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.

[9]  E. Arvat,et al.  Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. , 2014, Thyroid : official journal of the American Thyroid Association.

[10]  Chih-Kuang Chen,et al.  Polylactide-graft-doxorubicin nanoparticles with precisely controlled drug loading for pH-triggered drug delivery. , 2014, Biomacromolecules.

[11]  T. Chou,et al.  Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment , 2013, PloS one.

[12]  V. D. Di Crescenzo,et al.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.

[13]  A. K. Kondapi,et al.  A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer , 2013, Journal of Cancer.

[14]  F. Marano,et al.  Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. , 2013, Thyroid : official journal of the American Thyroid Association.

[15]  Jingmou Yu,et al.  Folic acid conjugated glycol chitosan micelles for targeted delivery of doxorubicin: preparation and preliminary evaluation in vitro , 2013, Journal of biomaterials science. Polymer edition.

[16]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[17]  Y. Nikiforov,et al.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[18]  C. Nucera,et al.  FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. , 2012, Endocrine-related cancer.

[19]  M. Trotta,et al.  New chitosan nanobubbles for ultrasound-mediated gene delivery: preparation and in vitro characterization , 2012, International journal of nanomedicine.

[20]  B. Bussolati,et al.  Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  N. Fortunati,et al.  Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer , 2012, Front. Endocrin..

[22]  B. Bussolati,et al.  Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo , 2012, International journal of cancer.

[23]  T. Kodama,et al.  Evaluation of antitumor effects following tumor necrosis factor‐α gene delivery using nanobubbles and ultrasound , 2011, Cancer science.

[24]  S. Remick,et al.  Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment , 2011, Journal of oncology.

[25]  R. Weber,et al.  Anaplastic thyroid carcinoma: palliation or treatment? , 2011, Current opinion in otolaryngology & head and neck surgery.

[26]  C. Nucera,et al.  Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. , 2010, Surgery.

[27]  J. Copland,et al.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[29]  N. Fortunati,et al.  Emerging molecular therapies of advanced thyroid cancer. , 2010, Molecular aspects of medicine.

[30]  Richard Manasseh,et al.  Cavitation microstreaming and stress fields created by microbubbles. , 2010, Ultrasonics.

[31]  Xiang Li,et al.  Preparation of nanobubbles for ultrasound imaging and intracelluar drug delivery. , 2010, International journal of pharmaceutics.

[32]  Ick Chan Kwon,et al.  Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Cristina Carvalho,et al.  Doxorubicin: the good, the bad and the ugly effect. , 2009, Current medicinal chemistry.

[34]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[35]  Raffi Karshafian,et al.  Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. , 2009, Ultrasound in medicine & biology.

[36]  Douglas A Christensen,et al.  Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. , 2008, Ultrasonics.

[37]  E. Lam,et al.  Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression , 2008, Molecular Cancer Therapeutics.

[38]  I. Kwon,et al.  Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[39]  R. Chiarle,et al.  High Energy Shock Waves (HESW) Increase Paclitaxel Efficacy in a Syngeneic Model of Breast Cancer , 2008, Technology in cancer research & treatment.

[40]  H. Katus,et al.  Impact of microbubbles on shock wave-mediated DNA uptake in cells in vitro. , 2007, Ultrasound in medicine & biology.

[41]  G. Ciccone,et al.  Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. , 2007, European journal of endocrinology.

[42]  R. Frairia,et al.  High energy shock waves activate 5'-aminolevulinic Acid and increase permeability to Paclitaxel: antitumor effects of a new combined treatment on anaplastic thyroid cancer cells. , 2007, Thyroid : official journal of the American Thyroid Association.

[43]  Kyung-Ja Cho,et al.  In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. , 2007, Biomaterials.

[44]  O. Bosco,et al.  Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. , 2006, The Journal of endocrinology.

[45]  A. Gartel,et al.  Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. , 2006, Cancer research.

[46]  D. L. Le Couteur,et al.  The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[47]  M. Schlumberger,et al.  Anaplastic Thyroid Carcinoma , 2003 .

[48]  R. Frairia,et al.  High Energy Shock Waves (HESW) Enhance Paclitaxel Cytotoxicity in MCF-7 Cells , 2003, Breast Cancer Research and Treatment.

[49]  I. Kwon,et al.  Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[50]  S. Chow,et al.  Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer , 2003, Anti-cancer drugs.

[51]  Michael R Hamblin,et al.  Shock wave-mediated molecular delivery into cells. , 2002, Biochimica et biophysica acta.

[52]  J. Ogden,et al.  Shock Wave Therapy (Orthotripsy®) in Musculoskeletal Disorders , 2001, Clinical orthopaedics and related research.

[53]  M. Israel,et al.  Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[54]  H. Gharib,et al.  Anaplastic thyroid carcinoma: current diagnosis and treatment. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  K Hynynen,et al.  Ultrasound technology for hyperthermia. , 1999, Ultrasound in medicine & biology.

[56]  P. Hofschneider,et al.  Shock wave permeabilization as a new gene transfer method , 1997, Gene Therapy.

[57]  J. Lingeman,et al.  Extracorporeal Shock Wave Lithotripsy , 1997 .

[58]  T. Skovsgaard,et al.  Cellular resistance to anthracyclines. , 1996, General pharmacology.

[59]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[60]  Ick Chan Kwon,et al.  Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. , 2006, Biomaterials.

[61]  R. Frairia,et al.  High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines. , 2006, Oncology reports.

[62]  Y. Nikiforov Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas , 2004, Endocrine pathology.